In August, Alcon released its second quarter and half-year financial results. According to a company press release, the second quarter saw sales of $1.2 billion, a decrease of 36%.
The decrease, which was mainly attributed to fallout from COVID-19, was partially offset by growth in sales of the PanOptix IOL and Pataday OTC, according to the release. Sales for the first half of 2020 were $3 billion, a 17% decrease, with the pandemic offsetting strong sales at the start of the year.
Following the release of these financial results, Healio/OSN (Read more...)
Uncategorized